SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cell Therapeutics (CTIC)
An SI Board Since August 1997
Posts SubjectMarks Bans Symbol
946 45 0 CTIC
Emcee:  Regis McConnell Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
921Figures. Leopard can't change its spots.rkrw-3/22/2008
920Item 5.02 Departure of Directors or Certain Officers; Election of Directors; ApIcebrg-3/22/2008
919CTI chief gets bonus to buy stock Last updated March 21, 2008 7:35 p.m. PT By JIcebrg-3/22/2008
918Not ever.DewDiligence_on_SI-3/21/2008
917Not to my knowledge, which however is somewhat limited. With the amounts he haIcebrg-3/21/2008
916Has he ever bought before?rkrw-3/21/2008
915Bianco buys shares. Message 24429038Icebrg-3/21/2008
914Layoffs aside, company throws party SEATTLE, Feb. 13 (UPI) -- With $19 million Icebrg-2/13/2008
913keokalani'nui-1/18/2008
912Cell Therapeutics to build ties to Italy New stock offering to raise $1.27 milliIcebrg-1/18/2008
911Researchers Detail Favorable Zevalin Data At ASH, But Also Medicare Concern TheIcebrg-1/3/2008
910<b>Giving away other people's money or at least something very close tIcebrg-12/31/2007
909Cell Therapeutics buys drug shown to shrink tumors Last updated December 27, 200Icebrg-12/28/2007
908Judge grants whistle-blower 15% in Cell Therapeutics case Company paid $10.5 milIcebrg-12/15/2007
907NHL Drug Threatened by Medicare Fee Cut Raises Progression-Free Survival by 2 YeIcebrg-12/12/2007
906<b>Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line TreatmenIan@SI-12/11/2007
905[643] 90Y-Ibritumomab Tiuxetan (Zevalin) Consolidation of First Remission in AdvIcebrg-11/12/2007
904Major Phase 3 Trial Shows Zevalin® Extends Progression-Free Survival in oneIcebrg-11/12/2007
903Tom; Great story huh? I was going to post but you beat me to it. This story wasSteve Lokness-10/26/2007
902A side story as part of the CTIC saga - WSJ: The New York Times Printer Friendltom pope-10/25/2007
901Phase I Trial of Poly-L-Glutamate Camptothecin (CT-2106) Administered Weekly in Icebrg-10/3/2007
900Study Shows Brostallicin in Combination with Cisplatin is Well-Tolerated and ProIcebrg-9/27/2007
899A bit of news this morning has the price up in the pm. Guess it is time for anoFindit-8/22/2007
898>>Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug tuck-8/16/2007
897Cell Therapeutics "market outperform" - update Friday, August 10, 200Icebrg-8/11/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News